"[This] is the first human study on DC-based immunotherapy in patients with mesothelioma," wrote Joachim G Aerts M.D., Ph.D., a pulmonary physician at Erasmus Medical Center in the Netherlands.
The findings have been published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
The U.S. and other developed countries have prohibited the use of asbestos for decades, but the time between asbestos exposure and diagnosis of mesothelioma can be up to 50 years. The incidence of mesothelioma, therefore, is still on the rise and expected to continue to increase until 2020. Once diagnosed, mesothelioma has a median survival time of 12 months. The standard chemotherapeutic treatment only improves survival time by about three months.
The anticipated increase in the incidence of mesothelioma, together with the paucity of treatment options, has spurred considerable interest in the development of new therapies. Immunotherapy, which uses the body's own immune system to target and destroy cancer cells, has been shown to have some promise.
"The possibility to harness the potency and specificity of the immune system underlies the growing interest in cancer immunotherapy," said Dr. Aerts. "One such approach uses the patient's own DC to present tumor-associated antigens and thereby generate tumor-specific immunity."
Building upon their previous research which demonstrated that DC vaccinations induced anti-tumor immunity and conferred a survival benefit in mice, Dr. Aerts and colleagues sought to test the clinical relevance of their finding. After recruiting 10 human patients recently diagnosed with malignant pleural mesothelioma of the epithelial subtype, they cultured immature DC from their blood and exposed the DC to the antigen produced by the patients' tumors. The DC were also exposed to keyhole limpet hemocyanin (KLH), which was used as a surrogate marker to show an immune response. The DC were then matured and injected back into the patients in three doses over a two-week interval.
Serum samples from all patients showed a significant increase of pre- versus post-vaccine antibodies to KLH. In the four patients whose tumor material was sufficient for testing, there was clear induction of cytotoxicity against their own tumors after vaccination. Three patients showed signs of tumor regression, though this could not be conclusively or directly attributed to the vaccine.
Encouragingly, while eight of the patients developed flu-like symptoms in response to the vaccinations, the symptoms normalized after one day in all but one of the patients. There were no signs of autoimmune diseases in the patients provoked by the vaccination, nor other serious side effects.
"The major problem in mesothelioma is that the immunosuppressive environment caused by the tumor will negatively influence our therapy so we are now working on a method to lower this immunosuppressive environment," said Dr. Aerts. "We hope that by further development of our method it will be possible to increase survival in patients with mesothelioma and eventually vaccinate persons who have been in contact with asbestos to prevent them from getting asbestos related diseases."
Email or share this story:|MoreStory Source:
The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by American Thoracic Society, via EurekAlert!, a service of AAAS.Journal Reference:
Joost P Hegmans, Joris D. Veltman, Margaretha E Lambers, I. Jolanda M. de Vries, Carl G. Figdor, Rudi W Hendriks, Henk C. Hoogsteden, Bart N. Lambrecht, and Joachim G. Aerts. Consolidative Dendritic Cell-Based Immunotherapy Elicits Cytotoxicity Against Malignant Mesothelioma. American Journal of Respiratory and Critical Care Medicine, 2010; DOI: 10.1164/rccm.200909-1465OCNeed to cite this story in your essay, paper, or report? Use one of the following formats: APAMLA
Note: If no author is given, the source is cited instead.
Related StoriesNew Technique Can Help Diagnose Mesothelioma (Aug. 25, 2009) — A new technique may help clinicians hone in on a diagnosis in patients presenting with a pleural effusion of unknown ... > read moreAsbestos Disease Projections Too Low (Apr. 4, 2007) — Current predictions of the future incidence of asbestos-related disease have been substantially underestimated, according to new modelling to be presented in Melbourne today by an epidemiologist from ... > read moreMouse Model For Mesothelioma Reproduces Human Disease (Mar. 11, 2008) — Scientists have established a mouse model for human malignant mesothelioma that will provide valuable insight into cancer development and progression along with new directions for design of ... > read moreExposure To Volcanic Mineral Associated With Increased Mesothelioma Incidence In Turkey (Mar. 20, 2006) — High exposure to a fibrous volcanic mineral called erionite was associated with a high incidence of a type of cancer called mesothelioma, according to a study in the March 15 issue of the Journal ... > read moreNaturally Occurring Asbestos Linked To Lung Cancer (July 15, 2005) — Everyday exposure to naturally occurring asbestos increases the risk of developing malignant mesothelioma, according to a study by UC Davis researchers. The study - the largest to examine the ... > read moreSearch ScienceDailyNumber of stories in archives: 86,814Find with keyword(s): Enter a keyword or phrase to search ScienceDaily's archives for related news topics,the latest news stories, reference articles, science videos, images, and books.
Just In:Life on Saturn's Moon Titan?Gulf Oil Spill Threatens Cold-Water ReefsAdolescent Brains Biologically Wired for RiskYangtze River�s Ancient Origins RevealedCould Life Survive on Mars? Yes, Expert SaysDrug Induces a Memory of Safety in Rat BrainsMongooses Pass Traditions on to Their YoungOasis Near Death Valley Fed by Ancient Aquifer Science Video News
Faster Flu VaccineSpraying viral genes directly through the skin is a new technique that turns infinitesimal amounts of DNA into an effective vaccine. If approved for. ... > full storyHematologists Boost Immune Response in Bone-Marrow Transplant PatientsMolecular Biologists Devise Strategy To Starve Brain TumorsPediatricians Reduce Ear Infections By Vaccinating Childrenmore science videos 
Copyright © 1995-2010 ScienceDaily LLC — All rights reserved — Contact: editor@sciencedaily.com
Part of the iVillage Your Total Health Network
View the Original article
0 comments:
Post a Comment